GlassScriptPhysician profile
Sheila A Branson
NPI 1760420400
$2,486.28
in general payments reported to CMS, 2019-2025
27 companies · $490 in 2025
The $490 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $475 · 2022: $253 · 2023: $750 · 2024: $518 · 2025: $490.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,758.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,758.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $670.85 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $352.10 | 2021-2024 | |
| Amgen INC. | $256.37 | 2021-2025 | Evenity, Otezla, Repatha |
| Pfizer INC. | $172.71 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $166.62 | 2021-2025 | Farxiga |
| Lilly USA, LLC | $153.80 | 2021-2024 | Mounjaro, Zepbound |
| Abbott Laboratories | $108.14 | 2022-2025 | Freestyle Libre 3 |
| Scpharmaceuticals INC. | $81.29 | 2024-2025 | |
| Radius Health, INC. | $67.21 | 2024-2025 | Tymlos |
| Daiichi Sankyo INC. | $58.23 | 2023-2025 | Injectafer |
| Takeda Pharmaceuticals U.S.A., INC. | $36.87 | 2021 | |
| Dexcom, INC. | $36.57 | 2023-2024 | Dexcom G6 Transmitter |
| Mylan Specialty L.P. | $34.81 | 2023-2024 | Yupelri |
| Corcept Therapeutics | $34.38 | 2025 | Korlym |
| Merck Sharp & Dohme LLC | $30.56 | 2025 | Capvaxive |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $29.45 | 2023 | Arexvy, Shingrix |
| Neurocrine Biosciences, INC. | $28.00 | 2025 | |
| Vanda Pharmaceuticals INC. | $23.02 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $19.85 | 2021 | |
| Smith+Nephew, INC. | $19.29 | 2024 | Grafix, Oasis |
| Viatris Specialty LLC | $18.53 | 2025 | Yupelri |
| Philips North America LLC | $18.48 | 2024 | (Ck6) Holter |
| Novartis Pharmaceuticals Corporation | $15.74 | 2021 | |
| Sumitomo Pharma America, INC. | $14.71 | 2025 | Gemtesa |
| Eisai INC. | $14.39 | 2021 | |
| Amarin Pharma, INC. | $12.87 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $11.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheila Branson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.